Albendazole vs Praziquantel for Therapy ...

Abstract

Contact us to discuss your requirements of Praziquantel Injection Uk. Our experienced sales team can help you identify the options that best suit your needs.

&#; Praziquantel and albendazole have been recently described as effective drugs for treating cysticercosis of the brain. In this study, effectiveness of each drug for therapy for parenchymal brain cysticercosis was compared. Twenty patients were treated either with albendazole or with praziquantel; in addition, five patients were taken as controls and treated only with symptomatic drugs. Three months after therapy, results showed that both drugs, albendazole and praziquantel, were highly effective, as seen by the disappearance of cystic lesions in computed tomographic scans. All lesions in control patients remained unchanged. Albendazole, when compared with praziquantel, showed a 76% vs 73% disappearance of lesions, respectively. It was concluded that both drugs have similar equivalent efficacy and greatly improve the therapeutics of cysticercosis.

CRD summary

This review concluded that albendazole was more effective than praziquantel for clinically important outcomes in the treatment of neurocysticercosis, but more comparative interventional studies were required to draw a safe conclusion about the best regimen. The conclusions should be interpreted with extreme caution due to possible publication bias and failure to consider study quality or investigate heterogeneity.

Authors' objectives

To compare the effectiveness and safety of albendazole and praziquantel for the treatment of neurocysticercosis.

Searching

PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched (search dates not reported). The search included all languages, but only studies published in English, French, German and Italian were evaluated. Search terms were reported. Reference lists were examined for additional studies.

Study selection

Prospective trials that compared albendazole with praziquantel in patients with neurocysticercosis infected with parasites in their cystic stage without perilesional inflammation were eligible for inclusion if they examined the partial or total disappearance of cysts and/or control of seizures. Studies using concomitant drugs were eligible for inclusion. The included studies were conducted in Mexico and Ecuador. Studies were mainly of parenchymal neurocysticercosis with varying levels of inflammation and cysts. Doses of albendazole ranged from 15mg/kg/day to 20mg/kg/day and praziquantel from 50mg/kg/day for varying lengths of treatment duration. Concomitant therapy consisted of at least antiepileptic drugs plus one or more of the following in the included studies: corticosteroids, analgesics, antiemetics and symptomatic medication. Follow-up ranged from three to 18 months. The primary outcome was the proportion of patients with controlled seizures. Secondary outcomes were reduction of cysts, total disappearance of cysts, adverse events related to the antihelminthic drugs and the side-effect intracranial hypertension.

Studies were selected independently by two reviewers. Disagreements were resolved by consensus among all reviewers.

Assessment of study quality

Randomised controlled trials (RCTs) were assessed for quality using the Jadad scale in terms of randomisation, blinding, withdrawals and allocation to produce a quality score out of 5. Other study designs were not assessed for quality. The reviewers (number not reported) independently assessed validity and disagreements were resolved by consensus amongst all reviewers.

Data extraction

Data were extracted for the outcomes control of seizures, reduction of cysts, total disappearance of cysts, mortality, total adverse events and intracranial hypertension. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. The authors did not state how the data were extracted.

Methods of synthesis

Odds ratios were pooled using the Mantel-Haenszel fixed-effect model and DerSimonian and Laird random-effects model and corresponding 95% CIs calculated. Results of the fixed-effects model were presented only when no statistically significant heterogeneity was present. For the outcome reduction of cysts a linear regression model was used to calculate a beta coefficient and corresponding 95% CIs. For analyses of seizure control, logarithms of rate ratios were combined with the inverse variance method. Statistical heterogeneity was assessed using the I2 test and Χ2 test. Publication bias was assessed with a funnel plot.

Results of the review

Six studies were included in the review (n=404): two RCTs (n=225) and four prospective studies (n=179). Both RCTs had a Jadad score of 3.

The company is the world’s best Praziquantel Importers from Japan supplier. We are your one-stop shop for all needs. Our staff are highly-specialized and will help you find the product you need.

Albendazole was associated with significantly better control of seizures than praziquantel (OR 4.94, 95% CI 2.45 to 9.98, p<0.; one RCT and three prospective studies, n=156) and total disappearance of cysts (OR 2.30, 95% CI 1.06 to 5.00, p=0.03; six studies, n=335) than praziquantel. There was strong evidence of statistical heterogeneity for both analyses (I2=51.2% and 50.3%, Χ2 p=0.07).

There was no significant difference between drugs for reduction of cysts, adverse events or intracranial hypertension. The authors reported that mortality data was inadequate to allow meaningful analysis.

Authors' conclusions

Albendazole was found to be more effective than praziquantel for clinically important outcomes. However, more comparative interventional studies were required to draw a safe conclusion about the best regimen.

Implications of the review for practice and research

Practice: The authors did not state any implications for practice.

Research: The authors stated that more studies, in particular RCTs with homogeneous regimens and longer follow-up periods, were required.

Funding

No specific funding.

Bibliographic details

Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLOS Neglected Tropical Diseases ; 2(3): e194. [PMC free article: PMC] [PubMed: ]

Original Paper URL

http://www.plosntds.org/article/info%3Adoi%2F10.%2Fjournal.pntd.

Indexing Status

Subject indexing assigned by NLM

MeSH

Albendazole /therapeutic use; Clinical Trials as Topic; Humans; Neurocysticercosis /drug therapy; Praziquantel /therapeutic use; Randomized Controlled Trials as Topic; Treatment Outcome

AccessionNumber

Record Status

This is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.

Want more information on Praziquantel Liquid for Livestock? Feel free to contact us.